Paolo Fundaro - Net Worth and Insider Trading
Paolo Fundaro Net Worth
The estimated net worth of Paolo Fundaro is at least $45 Million dollars as of 2023-06-06. Paolo Fundaro is the Director, 10% Owner of Intercept Pharmaceuticals Inc and owns about 4,021,028 shares of Intercept Pharmaceuticals Inc (ICPT) stock worth over $45 Million. Details can be seen in Paolo Fundaro's Latest Holdings Summary section.
Transaction Summary of Paolo Fundaro
Paolo Fundaro Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paolo Fundaro owns 1 companies in total, including Intercept Pharmaceuticals Inc (ICPT) .
Click here to see the complete history of Paolo Fundaro’s form 4 insider trades.
Insider Ownership Summary of Paolo Fundaro
|Ticker||Comapny||Transaction Date||Type of Owner|
|ICPT||Intercept Pharmaceuticals Inc||2020-05-28||director & 10 percent owner|
Paolo Fundaro Latest Holdings Summary
Paolo Fundaro currently owns a total of 1 stock. Paolo Fundaro owns 4,021,028 shares of Intercept Pharmaceuticals Inc (ICPT) as of August 17, 2020, with a value of $45 Million.
Latest Holdings of Paolo Fundaro
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
|ICPT||Intercept Pharmaceuticals Inc||2020-08-17||4,021,028||11.19||44,995,303|
Holding Weightings of Paolo Fundaro
Paolo Fundaro Form 4 Trading Tracker
According to the SEC Form 4 filings, Paolo Fundaro has made a total of 3 transactions in Intercept Pharmaceuticals Inc (ICPT) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Intercept Pharmaceuticals Inc is the sale of 1,500,000 shares on August 17, 2020, which brought Paolo Fundaro around $71 Million.
Insider Trading History of Paolo Fundaro
Paolo Fundaro Trading Performance
Paolo Fundaro Ownership Network
Ownership Network List of Paolo Fundaro
Ownership Network Relation of Paolo Fundaro
Paolo Fundaro Owned Company Details
What does Intercept Pharmaceuticals Inc do?
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Who are the key executives at Intercept Pharmaceuticals Inc?
Paolo Fundaro is the director & 10 percent owner of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .
Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Intercept Pharmaceuticals Inc Insider Transactions
Paolo Fundaro Mailing Address
Above is the net worth, insider trading, and ownership report for Paolo Fundaro. You might contact Paolo Fundaro via mailing address: C/o Genextra S.p.a.,, Via G. De Grassi, 11, Milan L6 20123.